Altman Peter 4

What Happened Peter Altman, President, CEO and a director of BioCardia (BCDA), did not sell stock in the open market. On July 2, 2026, 54,606 shares were withheld by the company to cover income tax/withholding obligations related to RSUs that vested June 29, 2026 (reported disposal value $67,711). On July 6, 2026, Altman was reported to have been granted 57,688 derivative shares (no cash paid), which will vest over time.

Key Details

• Transaction dates and amounts:
  • July 2, 2026 — 54,606 shares withheld (Disposition) at $1.24 per share; total reported value $67,711 (tax withholding; not an open-market sale) [F1].
  • July 6, 2026 — 57,688 derivative shares granted at $0.00 (award/derivative) [A].
• Shares owned after the transactions: not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: Shares were withheld by the issuer to satisfy income tax/withholding obligations from the RSU net settlement (not a market sale).
  • F2: The granted derivative vests 1/48th monthly beginning August 6, 2026, subject to continued service.
• Filing: Form 4 filed July 7, 2026 for a July 2 report date — this appears to fall within the normal Form 4 reporting window.

Context This filing reflects routine equity compensation administration (RSU net settlement and a new award) rather than an open-market purchase or sale. The July 2 "disposition" is a tax-withholding event tied to vested RSUs, not an indicator that the insider sold shares on the market. The July 6 grant is a time‑based derivative award (vesting monthly), so the reported grant does not represent immediately tradable common shares.